Ghost Tree Capital’s Puma Biotechnology PBYI Stock Holding History

Ghost Tree Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-200,000	Closed	-$6.14M	–	77
2016 Q4	$6.14M	Buy	+200,000	New	+$8.65M	1.48%	29

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ghost Tree Capital's PBYI Position: Q3 2018 in Review

Ghost Tree Capital sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 14,000 shares — an estimated $828K sold.

Ghost Tree Capital first reported a position in PBYI in Q4 2013 and held it in 13 quarters. The position peaked at $13.1M in Q2 2017. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

Ghost Tree Capital reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
Ghost Tree Capital sold 14,000 Puma Biotechnology shares in Q3 2018, an estimated $828K.
Ghost Tree Capital first reported a position in Puma Biotechnology in Q4 2013 and held it in 13 quarters.
Ghost Tree Capital's Puma Biotechnology position peaked at $13.1M in Q2 2017.
156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Ghost Tree Capital's 13F filing for Q3 2018, filed 14 Nov 2018.